Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tobi Podhaler

- PMLiVE

NICE consults on reducing melanoma cases

New guidance set to focus on diagnosing and managing the skin cancer  

- PMLiVE

NICE backs first ‘ultra-orphan’ drug Soliris

Final guidance backs Alexion’s treatment for very rare blood clot condition

Novartis building

Novartis sees first benefits from efficiency drive

Made $1.6bn in savings in 2014

- PMLiVE

Novartis begins sale talks for Horsham, UK site

Enters negotiations with the University of Brighton

- PMLiVE

Novartis launches another localised NHS eye service in UK

Will provide specialised care to people of Coventry

- PMLiVE

NICE heart attack recommendation for Xarelto

Bayer drug on course for another blood clot indication in England and Wales

- PMLiVE

Novartis’ Cosentyx cleared for psoriasis in Europe

First of the IL-17 inhibitor classof drug to receive European approval

- PMLiVE

CDF chair regrets undermining NICE

But Prof Clark says he wholeheartedly supports the Institute

- PMLiVE

NICE backs new hepatitis C treatments

But Sovaldi faces funding delay and Olysio not backed in all indications

- PMLiVE

NICE says cost of Dendreon’s cancer vaccine is too high

Another blow as the bankrupt company goes to auction next month

- PMLiVE

Novartis forms digital health investment company with Qualcomm

Expands work with Tricorder prize firm to develop 'beyond-the-pill' initiatives

Novartis building

Novartis files COPD combo in US

QVA149 combines long-acting beta agonist with long-acting muscarinic antagonist

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links